文献速递儿科与产科急症

妊娠期补充高剂量叶酸预防子痫前期(FACT):双盲、III期、随机对照、国际多中心试验

Effect of high dose folic acid supplementation in pregnancy on pre-eclampsia (FACT): double blind, phase III, randomised controlled, international, multicentre trial.
PubMed 文献 · BMJ · 2018-09-12
一句话结论对至少一项子痫前期高危因素的孕妇,妊娠早期后每日补充4.0 mg叶酸不能预防子痫前期(14.8% vs 13.5%,RR 1.10,95%CI 0.90–1.34,P=0.37)。

FACT试验为双盲、III期、国际多中心随机对照试验,在五个国家70个产科中心纳入2464名至少有一项子痫前期高危因素(孕前高血压、孕前糖尿病、双胎妊娠、既往子痫前期或BMI≥35)的孕妇,随机接受每日4.0 mg口服叶酸或安慰剂,从孕8周至孕16周末。主要终点子痫前期(孕20周后高血压伴大量蛋白尿或HELLP综合征)在叶酸组169/1144(14.8%)、安慰剂组156/1157(13.5%),RR 1.10(95%CI 0.90–1.34;P=0.37),无统计学差异。其他母儿不良结局两组间也无差异证据。结论:妊娠早期后补充4.0 mg/天叶酸不能预防高危孕妇的子痫前期。

要点

  • 对至少一项子痫前期高危因素的孕妇,孕8周至孕16周末每日口服4.0 mg叶酸,子痫前期发生率14.8%(169/1144) vs 安慰剂13.5%(156/1157),RR 1.10(95%CI 0.90–1.34;P=0.37),无统计学差异。
  • 其他母儿不良结局两组间无差异证据。
  • 适用人群为至少一项高危因素者:孕前高血压、孕前糖尿病(1型或2型)、双胎妊娠、既往子痫前期或BMI≥35。
  • 结论:妊娠早期后补充4.0 mg/天叶酸不能预防高危孕妇的子痫前期。

适用人群与场景

  • 孕妇,至少有一项子痫前期高危因素:孕前高血压、孕前糖尿病(1型或2型)、双胎妊娠、既往子痫前期或BMI≥35。
  • 2011至2015年间在五个国家(阿根廷、澳大利亚、加拿大、牙买加和英国)70个产科中心随机。

诊断标准与关键阈值

  • 子痫前期定义:孕20周后出现高血压,伴大量蛋白尿或HELLP综合征(溶血、肝酶升高、血小板减少)。

处置流程与药物剂量

  • eligible women随机接受每日高剂量叶酸(四片1.0 mg口服片)或安慰剂,从孕8周至孕16周末,直至分娩。
  • 临床医生、参与者、判定者和研究 staff 对治疗分配设盲。

研究设计与关键结果

  • 研究类型:双盲、III期、国际多中心随机对照试验;五个国家70个产科中心;2464名孕妇随机(叶酸组1144名,安慰剂组1157名),2301名纳入意向性治疗分析。
  • 主要终点:子痫前期在叶酸组169/1144(14.8%) vs 安慰剂组156/1157(13.5%),RR 1.10(95%CI 0.90–1.34;P=0.37),无统计学差异。
  • 其他母儿不良结局两组间无差异证据。

证据类型、等级与局限

  • 证据类型:随机对照试验(III期、双盲、国际多中心)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对至少一项子痫前期高危因素的孕妇,妊娠早期后每日补充4.0 mg叶酸不能预防子痫前期(14.8% vs 13.5%,RR 1.10,95%CI 0.90–1.34;P=0.37)。

指南或共识出处

  • FACT试验:Effect of high dose folic acid supplementation in pregnancy on pre-eclampsia (FACT): double blind, phase III, randomised controlled, international, multicentre trial;Trial registration: Current Controlled Trials ISRCTN23781770 and ClinicalTrials.gov NCT01355159。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To determine the efficacy of high dose folic acid supplementation for prevention of pre-eclampsia in women with at least one risk factor: pre-existing hypertension, prepregnancy diabetes (type 1 or 2), twin pregnancy, pre-eclampsia in a previous pregnancy, or body mass index ≥35.

DESIGN: Randomised, phase III, double blinded international, multicentre clinical trial.

SETTING: 70 obstetrical centres in five countries (Argentina, Australia, Canada, Jamaica, and UK).

PARTICIPANTS: 2464 pregnant women with at least one high risk factor for pre-eclampsia were randomised between 2011 and 2015 (1144 to the folic acid group and 1157 to the placebo group); 2301 were included in the intention to treat analyses.

INTERVENTION: Eligible women were randomised to receive either daily high dose folic acid (four 1.0 mg oral tablets) or placebo from eight weeks of gestation to the end of week 16 of gestation until delivery. Clinicians, participants, adjudicators, and study staff were masked to study treatment allocation.

MAIN OUTCOME MEASURE: The primary outcome was pre-eclampsia, defined as hypertension presenting after 20 weeks' gestation with major proteinuria or HELLP syndrome (haemolysis, elevated liver enzymes, low platelets).

RESULTS: Pre-eclampsia occurred in 169/1144 (14.8%) women in the folic acid group and 156/1157 (13.5%) in the placebo group (relative risk 1.10, 95% confidence interval 0.90 to 1.34; P=0.37). There was no evidence of differences between the groups for any other adverse maternal or neonatal outcomes.

CONCLUSION: Supplementation with 4.0 mg/day folic acid beyond the first trimester does not prevent pre-eclampsia in women at high risk for this condition.

TRIAL REGISTRATION: Current Controlled Trials ISRCTN23781770 and ClinicalTrials.gov NCT01355159.

来源:BMJ,查看原文。版权归原作者所有。

参考来源

  1. Wen SW, White RR, Rybak N, et al. Effect of high dose folic acid supplementation in pregnancy on pre-eclampsia (FACT): double blind, phase III, randomised controlled, international, multicentre trial. BMJ. 2018. PMID: 30209050. doi:10.1136/bmj.k3478

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。